Share on StockTwits

Antares Pharma (NASDAQ:ATRS) is scheduled to be releasing its Q114 earnings data on Friday, May 9th. Analysts expect Antares Pharma to post earnings of ($0.05) per share and revenue of $6.17 million for the quarter.

Antares Pharma (NASDAQ:ATRS) last announced its earnings results on Thursday, March 13th. The company reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.05) by $0.01. The company had revenue of $4.70 million for the quarter, compared to the consensus estimate of $6.20 million. During the same quarter in the previous year, the company posted ($0.04) earnings per share. The company’s revenue for the quarter was down 14.5% on a year-over-year basis. On average, analysts expect Antares Pharma to post $-0.16 EPS for the current fiscal year and $0.08 EPS for the next fiscal year.

Shares of Antares Pharma (NASDAQ:ATRS) opened at 2.79 on Thursday. Antares Pharma has a 52 week low of $2.43 and a 52 week high of $5.15. The stock has a 50-day moving average of $3.24 and a 200-day moving average of $4.00. The company’s market cap is $362.5 million.

Several analysts have recently commented on the stock. Analysts at Ladenburg Thalmann cut their price target on shares of Antares Pharma from $6.50 to $6.00 in a research note on Monday. Analysts at TheStreet downgraded shares of Antares Pharma from a “hold” rating to a “sell” rating in a research note on Monday, April 7th.

Antares Pharma, Inc (NASDAQ:ATRS) is a pharma company that focuses on self-injection pharmaceutical products and technologies and topical gel-based products.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.